专题：Melanoma and MAPK Pathways

This cluster of papers focuses on the mammalian MAP kinase signaling pathways, particularly their role in cancer, with a specific emphasis on melanoma. It covers the genetic mutations, targeted therapies, resistance mechanisms, and the impact of MAP kinase pathways on cell proliferation and immune response.
最新文献
Local Ras/actin signaling orients individual pseudopods in shallow gradients

article Full Text OpenAlex

Lipid Pocket Binders Impose Allosteric Changes of Protein Dynamics Around the Active Site of the Protein Kinase p38α

article Full Text OpenAlex

Clinical outcomes of genomically guided trametinib monotherapy across cancer types: results from the IMPRESS-Norway trial

article Full Text OpenAlex

Variable thresholds for phosphorylation targets of the ERK signaling pathway

article Full Text OpenAlex

Repotrectinib in NTRK fusion–positive advanced solid tumors: a phase 1/2 trial

article Full Text OpenAlex

Novel Compounds as MALT1 Inhibitors for Treating Cancer

article Full Text OpenAlex

Subpocket-Aware Fragment-Based Docking Pipeline for Kinase Ligand Design: Methodology and PKA Case Study

article Full Text OpenAlex

(E)-N'-(4-chlorobenzylidene)-5-methyl-1H-pyrazole-3-carbohydrazide as a potential PI3Kα targeting scaffold, synthesis, X-ray crystallography, DFT, molecular docking, molecular dynamics simulations, and MMGBSA analysis

article Full Text OpenAlex

Covalent inhibitor design confers activity against both GDP- and GTP-bound forms of KRAS G12C

article Full Text OpenAlex

Can We Navigate the Pitfalls of Tofacitinib RCTs in Vitiligo? Addressing Long-Term Safety and Generalizability for Enhanced Clinical Translation

article Full Text OpenAlex

近5年高被引文献
Relatlimab and Nivolumab versus Nivolumab in Untreated Advanced Melanoma

article Full Text OpenAlex 1661 FWCI166.207

Targeting the RAS/RAF/MAPK pathway for cancer therapy: from mechanism to clinical studies

article Full Text OpenAlex 672 FWCI105.0656

Cutaneous melanoma

review Full Text OpenAlex 588 FWCI137.5451

Long-Term Outcomes With Nivolumab Plus Ipilimumab or Nivolumab Alone Versus Ipilimumab in Patients With Advanced Melanoma

article Full Text OpenAlex 557 FWCI57.7531

Anti-tumor efficacy of a potent and selective non-covalent KRASG12D inhibitor

article Full Text OpenAlex 471 FWCI37.6835

Pan-KRAS inhibitor disables oncogenic signalling and tumour growth

article Full Text OpenAlex 454 FWCI71.5074

Pembrolizumab versus placebo as adjuvant therapy in completely resected stage IIB or IIC melanoma (KEYNOTE-716): a randomised, double-blind, phase 3 trial

article Full Text OpenAlex 450 FWCI45.3206

Combination Dabrafenib and Trametinib Versus Combination Nivolumab and Ipilimumab for Patients With Advanced BRAF-Mutant Melanoma: The DREAMseq Trial—ECOG-ACRIN EA6134

article Full Text OpenAlex 405 FWCI34.8211

Final, 10-Year Outcomes with Nivolumab plus Ipilimumab in Advanced Melanoma

article Full Text OpenAlex 359 FWCI104.7096

Dabrafenib plus trametinib in patients with BRAF V600E-mutant anaplastic thyroid cancer: updated analysis from the phase II ROAR basket study

article Full Text OpenAlex 322 FWCI25.7033